Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens

Xingchen Bian¹,²,³,⁴†, Xiaofen Liu¹,²,³†, Fupin Hu¹, Meiqing Feng⁴, Yuancheng Chen⁵, Phillip J. Bergen⁶, Jian Li⁶, Xin Li¹,²,³, Yan Guo¹* and Jing Zhang¹,²,³,⁵*

¹Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China, ²Key Laboratory of Clinical Pharmacology of Antibiotics, Shanghai, China, ³National Health Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China, ⁴Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, China, ⁵Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China, ⁶Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC, Australia

The latest PK/PD findings have demonstrated negligible efficacy of intravenous polymyxins against pulmonary infections. We investigated pharmacokinetic/pharmacodynamic (PK/PD)-based breakpoints of polymyxin B for bloodstream infections and the rationality of the recent withdrawal of polymyxin susceptibility breakpoints by the CLSI. Polymyxin B pharmacokinetic data were obtained from a phase I clinical trial in healthy Chinese subjects and population pharmacokinetic parameters were employed to determine the exposure of polymyxin B at steady state. MICs of 1,431 recent clinical isolates of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae collected from across China were determined. Monte-Carlo simulations were performed for various dosing regimens (0.42–1.5 mg/kg/12 h via 1 or 2-h infusion). The probability of target attainment, PK/PD breakpoints and cumulative fraction of response were determined for each bacterial species. MIC₉₀ of polymyxin B was 1 mg/L for P. aeruginosa and 0.5 mg/L for A. baumannii and K. pneumoniae. With the recommended polymyxin B dose of 1.5–2.5 mg/kg/day, the PK/PD susceptible breakpoints for P. aeruginosa, A. baumannii and K. pneumoniae were 2, 1 and 1 mg/L respectively for bloodstream infection. For Chinese patients, polymyxin B dosing regimens of 0.75–1.5 mg/kg/12 h for P. aeruginosa and 1–1.5 mg/kg/12 h for A. baumannii and K. pneumoniae were appropriate. Breakpoint determination should consider the antimicrobial PK/PD at infection site and delivery route. The recent withdrawal of polymyxin susceptible breakpoint by CLSI primarily based on poor efficacy against lung infections needs to be reconsidered for bloodstream infections.

Keywords: susceptibility breakpoint, polymyxin B, PK/PD analysis, Monte-Carlo simulation, bloodstream infection
INTRODUCTION

Carbapenem-resistant Gram-negative bacteria are a serious threat to global health. In China, approximately 20–30% of Pseudomonas aeruginosa and Klebsiella spp. and >70% of Acinetobacter spp. are now carbapenem resistant (http://www.chinets.com/). Elsewhere, the World Health Organization has reported high median resistance rates to carbapenems in several bacterial species globally, exemplified by resistance rates in Klebsiella spp. and Acinetobacter spp. isolated from bloodstream infections of ~20 and ~60%, respectively (2020; https://www.who.int/glass/resources/publications/early-implementation-report-2020/en/). Although the newly developed β-lactam/β-lactamase inhibitor combinations (such as ceftazidime-avibactam and ceftolozane-tazobactam) have mitigated the situation, none of them is active against metallo-β-lactamase-producing Enterobacteriales, P. aeruginosa or carbapenemase-producing A. baumannii (Yahav et al., 2020). Given many of these carbapenem-resistant bacteria remain susceptible to polymyxins (polymyxin B and colistin), this once abandoned class of antibiotics is often the only viable treatment option were revived and being listed on the reserve list of antibiotics by WHO (Jian et al., 2019).

The polymyxins are cyclic lipopeptides naturally produced by the Gram-positive Paenibacillus polymyxa (Velkov et al., 2019). While various polymyxins have been described, only polymyxin B and E (the latter known as colistin) are available for clinical use (Ross et al., 1959; Clifford and Stewart, 1961). The antimicrobial activity is initiated by an electrostatic attraction, causing displacement of divalent cations (Ca^{2+} and Mg^{2+}) that bridge adjacent LPS molecules and resulting in OM leaflet expansion, disruption of the membrane integrity, and increased membrane permeability (Berglund et al., 2015; Rabanal and Cajal, 2017). Prior to 2020, the Clinical and Laboratory Standards Institute (CLSI) provided susceptible and resistant breakpoints for colistin and polymyxin B (e.g., M100-S29). However, in 2020 the susceptible interpretative category (previously ≤2 mg/L in all cases) was removed (M100-S30). In contrast, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) has maintained the “susceptible” category for colistin (polymyxin B breakpoints are not reported) (Version 10.0, 2020). The decision by the CLSI was based primarily on data suggesting that intravenous polymyxins have limited efficacy for the treatment of lung infections in mice and patients (Rigatto et al., 2013; Cheah et al., 2015; Landersdorfer et al., 2018; Satlin et al., 2020). Indeed, studies in animals clearly show reduced bacterial killing in lung infection models compared to thigh infection models with equivalent parenteral dosage regimens (Cheah et al., 2015; Landersdorfer et al., 2018), and substantially lower concentrations of polymyxin B in epithelial lining fluid (ELF) compared to plasma have been reported following intravenous administration (He et al., 2013). Such data clearly suggests relatively low unbound concentrations are achieved in pulmonary fluids (He et al., 2013). Given that higher polymyxin concentrations can be achieved elsewhere in the body (e.g., blood), the CLSI decision to remove the susceptible category for polymyxins based primarily on lung infection data may not be justified for other infection sites such as the bloodstream.

Various historical factors led to colistin being adopted far more widely than polymyxin B. Consequently, most existing polymyxin studies involve colistin and its inactive prodrug, colistin methanesulfonate (CMS) (Tsuij et al., 2019). Recently, however, the use of polymyxin B for treatment of systemic infections has increased, primarily due to better PK characteristics and relatively lower rates of nephrotoxicity than CMS (Aggarwal and Dewan, 2018; Tsuij et al., 2019). Unfortunately, very few clinical studies have utilized polymyxin B (Kvitko et al., 2011; Rigatto et al., 2013; Terayama et al., 2017). Given the circumstances described here, we investigated susceptibility breakpoints for polymyxin B for treatment of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria and the rationality of the recent withdrawal of the ‘susceptible’ category for polymyxins by the CLSI. Clinical breakpoints were determined by epidemiological cut-offs, PK/PD breakpoints and clinical efficacy (Li et al., 2015). To acquire PK/PD breakpoints, we conducted a PK study in healthy Chinese volunteers (Liu et al., 2021) and collected 1,431 isolates of P. aeruginosa, A. baumanii and K. pneumoniae from patients across China for PK/PD analysis. This study will provide useful information of PK/PD breakpoints for polymyxin B in patients and evaluate polymyxin dosing regimens for bloodstream infections caused by different bacterial species.

MATERIALS AND METHODS

Pharmacokinetics of Polymyxin B

A single-center, randomized, open-label phase I clinical trial of intravenous polymyxin B (0.75 and 1.5 mg/kg) were conducted in healthy Chinese subjects (Liu et al., 2021). The liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay of polymyxin B was employed to determine the concentrations as previously reported (Liu et al., 2020). Non-compartment analysis was employed to calculate the {AUC}_{0→inf} of polymyxin B in WinNonlin (v8.0, Pharsight, United States), which was linear with dose according to a power model with a 95% confidence interval (0.94, 1.2). Population pharmacokinetic (PPK) analysis was conducted using NONMEM 7.4 (Icon Development Solutions, Ellicott City, MD) with G77 FORTRAN compiler and FOCEI algorithm. The base model of polymyxin B was fit into a three-compartment model. The interindividual and residual variabilities were best described by an exponential model and a proportional model, respectively. Age and gender were included in the final PK model (Liu et al., 2021).

Microbiological Information

A total of 1,431 clinical isolates (517 strains of P. aeruginosa, 262 of A. baumanii and 652 of K. pneumoniae) were collected across 2017–2019 from more than 30 teaching hospitals in 23 provinces across China. Polymyxin B and meropenem minimum inhibitory concentrations (MICs) were determined by broth microdilution.
and interpreted according to the CLSI breakpoints (M100-S30, 2020). *Escherichia coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603 acted as quality control strains. Statistical analysis was performed using WHONET (version 5.6). The study protocol was approved by the Institutional Review Board of Huashan Hospital, Fudan University (no. 2018-408, no. 2019-460).

**Pharmacokinetic/Pharmacodynamic Targets for Polymyxin B Against the Three Gram-Negative Pathogens**

The area under the unbound concentration-time curve over 24 h to the MIC ratio (fAUC0–24h/MIC) is the most predictive PK/PD index for polymyxins (Tam et al., 2005; Bergen et al., 2008; Bergen et al., 2010; Cheah et al., 2015; Landersdorfer et al., 2018). PK/PD targets of 1-log10 CFU and 2-log10 CFU reductions in colony forming units (CFU)/thigh were derived from dose-fractionation studies of polymyxin B (*K. pneumoniae*) and colistin (*P. aeruginosa* and *A. baumannii*) in murine thigh infection models (Supplementary Table S1; Cheah et al., 2015; Landersdorfer et al., 2018). Given polymyxin B and colistin have essentially identical *in vitro* potencies and spectra of antibacterial activity (Gales et al., 2011), the colistin targets were adopted for polymyxin B. An unbound fraction (f) of polymyxin B in plasma of 42% was applied (Sandri et al., 2013).

**Probability of Target Attainment, Pharmacokinetic/Pharmacodynamic Breakpoints and Cumulative Fraction of Response**

Four thousand data sets were generated with the final PPK model based on the estimated PPK parameters for each dosage regimen ranging from 0.42 to 1.5 mg/kg/12 h (administered via a 1- or 2-h infusion). Mean and SD of AUC0–24hss were calculated using the simulated AUC0–24hss– Monte-Carlo simulations for PTA and CFR were performed using MATLAB (Mathworks, United States, version 7.0.1). The add-in macro permitted the MATLAB program to perform Monte-Carlo simulations for 10,000 simulated data sets (AUC0–24hss ± SD). The upper limit of the MIC range was taken as the PK/PD breakpoint when PTA was >90%. MIC distributions of polymyxin B for each bacterial species were used to determine the CFR, with a CFR of 90% considered effective.

**RESULTS**

**Susceptibility and PK Data**

Polymyxin B MIC distributions and MIC50/MIC90 values for the 1,431 clinical isolates are shown in Table 1. MICs ranged between 0.125 and >32 mg/L for *P. aeruginosa*, 0.25 to >32 mg/L for *A. baumannii*, and 0.25–16 mg/L for *K. pneumoniae*. Meropenem resistance was detected in 25.9, 85.5 and 37.0% of *P. aeruginosa*, *A. baumannii* and *K. pneumoniae* isolates, respectively. The AUC0–24hss achieved with different polymyxin B dosing regimens (0.42–1.5 mg/kg/12 h) and infusion times (1 or 2 h) are shown in Supplementary Table S2. Steady-state exposures (range, 26.2–93.7 mg/h/L) increased in proportion to the dose.

**Pharmacokinetic/Pharmacodynamic Analysis of Polymyxin B With Different Dosing Regimens**

Figures 1–3 and Supplementary Table S3 show the MIC distributions and PTA for each dosing regimen at steady state against strains of each bacterial species with diverse MICs. For *P. aeruginosa*, the fAUC0–24h/MIC required to achieve 1- and 2-log10 CFU killing (fAUC0–24h/MIC of 10 and 13.5, respectively) were achieved in 100% of cases for MICs ≤0.5 and ≤1 mg/L with the lower-dose regimens (0.42 and 0.75 mg/kg/12 h, respectively). However, with these regimens the PTA decreased dramatically as MICs increased above these values. For an MIC of 2 mg/L, the 1 mg/kg/12 h dosing regimen was effective with a PTA for 1-log10 CFU killing of 99% and the PTA for the 1.25 mg/kg/12 h dosing regimen was 95.1% to achieve 2-log10 CFU killing (Figure 1).

Against *A. baumannii*, both the 0.42 and 0.75 mg/kg/12 h regimens at steady state effectively achieved the fAUC0–24h/MIC target of 17.6 (2-log10 CFU reduction) against strains with MICs ≤0.5 mg/L (PTA = 97.5 and 100%), while the remaining dosing regimens were additionally effective against strains with an MIC ≤1 mg/L (PTA = 100%). No dosing regimen achieved the fAUC0–24h/MIC target of 17.6 when the MIC was ≥2 mg/L.

For *K. pneumoniae*, 0.42 and 0.75 mg/kg/12 h achieved the fAUC0–24h/MIC target of 17.4 in 98.1 and 100% of cases against strains with MICs ≤0.5 mg/L, respectively. All higher-dose regimens were additionally effective against strains with a MIC of ≤1 mg/L (PTA = 100%, Figure 3).

With the exception of the lowest dose regimen (0.42 mg/kg/12 h) against *P. aeruginosa*, all dosing regimens achieved a CFR >90% for all three bacterial species (MICs ranging from 0.125 to >32 mg/L; Table 2). The maximum treatable MICs for each bacterial species with the examined dosing regimens are shown in Table 3. Based on the dosing regimens of polymyxin B recommended throughout most of the world (1.5–2.5 mg/kg/day) and the highest fAUC0–24h/MIC target value, the PK/PD susceptibility breakpoints for *P. aeruginosa*, *A. baumannii* and *K. pneumoniae* were 2, 1 and 1 mg/L, respectively, for bloodstream infection. These breakpoints are higher than MIC90 values of current clinical isolates of all three bacterial species in China (Table 1), indicating the potential usefulness of polymyxin B for treatment of bloodstream infections caused by these bacteria.

**DISCUSSION**

Removal of the “susceptible” interpretation category for polymyxins by CLSI was driven primarily by lung infection data (He et al., 2013; Landersdorfer et al., 2018). However, polymyxins exhibit concentration-dependent killing against Gram-negative bacteria and efficacy is highly dependent upon concentrations achieved at the target site (Lee et al., 2019). For
bloodstream infections, the average steady-state concentrations \( (C_{ss,avg}) \) achieved with intravenously administered polymyxin B (0.45–3.38 mg/kg/day) or CMS (2–18 MIU/day) are 2–3 mg/L (polymyxin B and colistin) in critically-ill patients (Sandri et al., 2013; Nation et al., 2017). Thus, polymyxins may still be an appropriate therapeutic choice for bloodstream infections. The recent removal of the breakpoints for polymyxins by CLSI has caused significant uncertainties regarding their efficacy against bloodstream infections caused by the three aforementioned problematic Gram-negative bacteria. Therefore, we collected MIC data in the latest surveillance program in China and evaluated the rationality of the CLSI breakpoint modification for bloodstream infections.

In China, the MIC_{90} of polymyxin B for the three bacterial species were relatively low (1 mg/L for \( P. \) aeruginosa and 0.5 mg/L for \( A. \) baumannii and \( K. \) pneumoniae; Table 1) and the 0.75 mg/kg/12 h regimen was effective against >90% of pathogens. However, the success of this regimen will depend on regional susceptibility data. According to the SENTRY antimicrobial surveillance program for bloodstream infections (data collected from 45 nations including China between 1997 and 2016) (Diekema et al., 2019), the MIC_{90} of colistin for \( P. \) aeruginosa (7,107 isolates), \( A. \) baumannii or \( A. \) calcoaceticus (3,124 isolates) and Enterobacteriaceae (54,476 isolates) was 2, 2, and >4 mg/L, respectively. Given substantial regional susceptibility differences, effective therapeutic regimens must

### Table 1: Polymyxin B MIC distributions for \( P. \) aeruginosa, \( A. \) baumannii and \( K. \) pneumoniae.

| Strain | MIC_{50} (mg/L) | MIC_{90} (mg/L) | MIC (mg/L) distribution (%) |
|--------|----------------|----------------|----------------------------|
|        | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | >32 |
| Pa (517) | 1     | 1    | 0.39 | 0.58 | 7.74 | 87.8 | 1.93 | 1.35 | 0 | 0 | 0 | 0.19 |
| Ab (262) | 0.5   | 0.5  | 0    | 1.53 | 93.1 | 4.96 | 0 | 0 | 0 | 0 | 0 | 0.38 |
| Kp (652) | 0.5   | 0.5  | 0.46 | 26.1 | 65.5 | 4.91 | 1.84 | 0.15 | 0.61 | 0 | 0 | 0 |

\*Resistance to meropenem (i.e., MIC ≥8 mg/L for \( P. \) aeruginosa and \( A. \) baumannii; MIC ≥4 mg/L for \( K. \) pneumoniae) was detected in 25.9% of \( P. \) aeruginosa isolates, 85.5% of \( A. \) baumannii isolates, and 37.0% of \( K. \) pneumoniae isolates. MIC_{50} the MIC value at which ≥50% of isolates are inhibited; MIC_{90} the MIC value at which ≥90% of isolates are inhibited.
consider the regional susceptibility of the bacterial species involved. In a recent Chinese study investigating the clinical efficacy and safety of polymyxin B-based regimens (100–200 mg/day, ≥5 days) for treatment of bloodstream infection caused by extensively-drug resistant Gram-negative bacteria, the clearance rate of microorganisms was 65.2%, overall effectiveness (cure or improvement) 59.0%, and 28-day all-cause mortality 41.0% (Zhao et al., 2020). Importantly, both effectiveness and microbial clearance were significantly higher
with higher daily doses of polymyxin B (150 and 200 mg) compared to the lowest daily dose (100 mg). This is in agreement with other clinical data which support the use of high doses of polymyxin B for bloodstream infections (Elías et al., 2020; Cai et al., 2020).

The recommended dose of intravenously administered polymyxin B throughout much of the world is 1.5–2.5 mg/kg/day with a loading dose of 2–2.5 mg/kg (Tsuji et al., 2019). In China, the only brand of polymyxin B currently available has a recommended intravenous dose of 50–100 mg/day (Polymyxin B for injection (Daily Med, 2017), equivalent to 0.42–0.83 mg/kg/12 h) for a 60 kg patient. Importantly, Lakota et al. (2018) proposed that for pathogens with MICs ≤0.75 mg/L, the target AUC0–24h,ss for polymyxin B should be 50–100 mg h/L. In our study, the polymyxin B AUC0–24h,ss achieved with the 0.42 and 0.75 mg/kg/12 h dosing regimens fell below this target range (AUC0–24h,ss of 26.2 and 46.9 mg h/L, respectively; Supplementary Table S2), indicating that the recommended dose in China is very likely insufficient. Loading doses have no impact on the exposure at steady state but in favour of the rapid achievement to the effective concentrations at day 1. From our previous population pharmacokinetic analysis, gender and age are covariates in the final model (Liu et al., 2021). However, both of them had no significant effect on the AUC0–24h,ss. If the new CLSI breakpoints (M100-S30, 2020) are employed, the recent MIC data collected in Chinese hospitals showed that most isolates of P. aeruginosa, A. baumannii, and K. pneumoniae (MIC90 values of 1, 0.5, and 0.5 mg/L, respectively) would have intermediate susceptibility to polymyxin B. However, further PK/PD analysis showed that increasing doses could be effective against strains with MICs up to 2 mg/L. Taking decreases in bacterial counts of 1-log10 CFU (for K. pneumoniae) or 2-log10 CFU (for P. aeruginosa and A. baumannii) kill as the target values, dosing regimens of ≥0.75 mg/kg/12 h could be effective against P. aeruginosa with MIC of 1 mg/L; for A. baumannii and K. pneumoniae, all dosing regimens were effective against isolates with MIC ≤0.5 mg/L. One PK/PD study on polymyxin B for bloodstream infections has been conducted though the rationality of the present CLSI breakpoints were not well explained which is a valuable reference in clinical practice (Wu et al., 2021). In addition, the possible effects from variabilities of protein binding and PK/PD targets were not fully investigated. Based on the recommended polymyxin B dose of 1.5–2.5 mg/kg/day, we have proposed here PK/PD susceptibility breakpoints for P. aeruginosa, A. baumannii and K. pneumoniae of 2, 1 and 1 mg/L, respectively. Thus, EUCAST interpretation standards would be recommended in terms of PK/PD. Given strain-to-strain variability in PD targets, we conducted sensitivity analysis using different PK/PD targets (7.4 for P. aeruginosa and A. baumannii and 28.0 for K. pneumoniae). The breakpoints for P. aeruginosa, A. baumannii and K. pneumoniae were 2, 2 and 1 mg/L, respectively. The variable protein binding may affect the PK/PD breakpoints as well. According to the reported protein binding of 78.5–92.4% (Zavascki et al., 2008), the breakpoints were 1, 0.5, 0.5 mg/L assuming protein binding rate was 78.5% and 0.25, 0.25, 0.25 mg/L using the value of 92.4% for P. aeruginosa, A. baumannii and K. pneumoniae. The protein binding of less than 80% is acceptable for treating infections caused by these three bacterial species. Clearly, for all three pathogens polymyxin B would not be

### Table 2: Cumulative fraction of response (CFR) to different dosing regimens of polymyxin B against P. aeruginosa, A. baumannii and K. pneumoniae.

| Dose (mg/kg) | Infusion time (h) | Dosing frequency | CFR for different AUC/MIC targets* (%) |
|-------------|------------------|-----------------|---------------------------------------|
|             |                  |                 | P. aeruginosa (517 isolates) | A. baumannii (262 isolates) | K. pneumoniae (652 isolates) |
|             |                  |                 | Target = 10.0 | Target = 13.5 | Target = 13.9 | Target = 17.6 | Target = 17.4 |
| 0.42        | 1                 | q12h            | 78.8         | 12.3         | 94.8         | 92.3         | 90.9 |
| 0.75        | 1                 | q12h            | 97.3         | 96.5         | 99.6         | 98.5         | 96.7 |
| 1.0         | 1                 | q12h            | 98.2         | 97.1         | 99.6         | 96.6         | 97.4 |
| 1.25        | 1                 | q12h            | 98.8         | 98.6         | 99.5         | 99.5         | 97.8 |
| 1.5         | 2                 | q12h            | 98.9         | 98.2         | 99.5         | 99.5         | 99.1 |

*Targets are the median target values for 1-log10 CFU and 2-log10 CFU reductions in CFU killing in murine thigh infection models (Cheah et al., 2015; Landersdorfer et al., 2018).

### Table 3: Susceptible breakpoints for isolates of P. aeruginosa, A. baumannii and K. pneumoniae based on the PK/PD of polymyxin B.

| Dose (mg/kg) | Infusion time (h) | Dosing frequency | PK/PD breakpoint |
|-------------|------------------|-----------------|-----------------|
|             |                  |                 | P. aeruginosa | A. baumannii | K. pneumoniae |
|             |                  |                 | MIC90 = MIC50 = 1 mg/L | MIC90 = MIC50 = 0.5 mg/L |
|             |                  |                 | Target = 10.0 | Target = 13.5 | Target = 13.9 | Target = 17.6 | Target = 17.4 |
| 0.42        | 1                 | q12h            | 0.5          | 0.5          | 0.5          | 0.5          |
| 0.75        | 1                 | q12h            | 1            | 1            | 1            | 0.5          | 0.5 |
| 1.0         | 1                 | q12h            | 2            | 1            | 1            | 1            | 1 |
| 1.25        | 1                 | q12h            | 2            | 2            | 2            | 1            | 1 |
| 1.5         | 2                 | q12h            | 2            | 2            | 2            | 1            | 1 |
recommended for the treatment of bloodstream infections when the pathogen MIC is >2 mg/L.

Xie et al. compared the efficacy and safety of polymyxin B in various patient populations (Xie et al., 2020). Exposure was noticeably influenced by patient body weight when doses were calculated in mg/kg. The lower exposures achieved in patients with less body weight such as 50 kg in comparison to patients with body weight of 75–100 kg are more likely to result in treatment failure. This is important to note the recommended dose of polymyxin B in China (50–100 mg/day) is not based on body weight. The lower end of the recommended dosing range in most Western countries (1.5 mg/kg/day) equals to 90 mg/day for a 60 kg patient. Utilizing polymyxin B over 90 mg/kg is essential in terms of PK/PD.

In summary, the determination of breakpoints should be species- and infection-site specific and underpinned by solid PK/PD data. Given the polymyxins remain important last-line antibiotics for the treatment of infections caused by carbapenem-resistant Gram-negative bacteria, appropriate PK/PD considerations must be given when determining their breakpoints and dosage regimens. Adequate doses (i.e., 90–100 mg/day) should be utilized in terms of Chinese recommended dosing range. The revival of CLSI susceptibility breakpoint of polymyxins for bloodstream infections is potential in the future.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of Huashan Hospital, Fudan University. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

XCB, BP, and JL wrote the manuscript; JZ, FPH, and MQF designed the research; XCB, XFL, and YG performed the research; XCB, XFL, and XL analyzed the data; YCC contributed new reagents/analytical tools.

FUNDING

This research was supported by the Science and Technology Commission of Shanghai Municipality (grant number 17DZ1910402, 17DZ1910403 and 19411964900); Major Research and Development Project of Innovative Drugs, Ministry of Science and Technology of China (grant number 2017ZX09304005).

ACKNOWLEDGMENTS

This work was performed in Huashan Hospital affiliated to Fudan University; the pharmacokinetic study was conducted in the Phase I Unit and the pharmacodynamic data were acquired from the Clinical Microbiology Laboratory, Huashan Hospital.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.785893/full#supplementary-material

REFERENCES

Aggarwal, R., and Dewan, A. (2018). Comparison of Nephrotoxicity of Colistin with Polymyxin B Administered in Currently Recommended Doses: A Prospective Study. Ann. Clin. Microbiol. Antimicrob. 17 (1), 15. doi:10.1186/s12941-018-0262-0

Bergen, P. J., Bulitta, J. B., Forrest, A., Tsuji, B. T., Li, J., and Nation, R. L. (2010). Pharmacokinetic/pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model. Antimicrob. Agents Chemother. 54 (9), 3783–3789. doi:10.1128/AAC.00903-09

Bergen, P. J., Li, J., Nation, R. L., Turnidge, J. D., Coulthard, K., and Milne, R. W. (2008). Comparison of once-, Twice- and Thrice-Daily Dosing of Colistin on Antibacterial Effect and Emergence of Resistance: Studies with Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model. J. Antimicrob. Chemother. 61 (3), 636–642. doi:10.1093/jac/dkm511

Berglund, N. A., Piggot, T. J., Jefferies, D., Sessions, R. B., Bond, P. J., and Khalid, S. (2015). Interaction of the Antimicrobial Peptide Polymyxin B1 with Both Membranes of E. coli: A Molecular Dynamics Study. Plos Comput. Biol. 11 (4), e1004180. doi:10.1371/journal.pcbi.1004180

Cai, Y., Leck, H., Tan, R. W., Teo, J. Q., Lim, T. P., Lee, W., et al. (2020). Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study. Antibiotics 9 (8), 451. doi:10.3390/antibiotics9080451

Cheah, S. E., Wang, J., Nguyen, V. T., Turnidge, J. D., Li, J., and Nation, R. L. (2015). New Pharmacokinetic/pharmacodynamic Studies of Systemically Administered Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in Mouse Thigh and Lung Infection Models: Smaller Response in Lung Infection. J. Antimicrob. Chemother. 70 (12), 3291–3297. doi:10.1093/jac/dkv267

Clifford, H. E., and Stewart, G. T. (1961). Intraventricular Administration of a New Derivative of Polymyxin B for Infection due to Ps. Pyocyanea. Lancet 2 (7195), 177–180. doi:10.1016/s0140-6736(61)90464-0

Daily Med (2017). Polymyxin B for Injection [package Insert]. China: Shanghai First Biochemical Pharmaceutical Co., Ltd.

Dickema, D. J., Hsueh, P. R., Mendes, R. E., Pfaffer, M. A., Rolston, K. V., Sader, H. S., et al. (2019). The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 63 (7), e00355–00319. doi:10.1128/AAC.00355-19
Gales, A. C., Jones, R. N., and Sader, H. S. (2011). Contemporary Activity of Polymyxin B Against a Worldwide Collection of Gram-Negative Pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2006-09). J. Antimicrob. Chemother. 66 (9), 2070–2074. doi:10.1093/jac/dkb239

He, J., Abdelraouf, K., Ledesma, K. R., Chow, D. S., and Tam, V. H. (2013). Pharmacokinetics and Efficacy of Liposomal Polymyxin B in a Murine Pneumonia Model. Int. J. Antimicrob. Agents 42 (6), 599–564. doi:10.1016/j.ijantimicag.2013.07.009

Jian, L., Nation, R., and Kaye, K. (2019). Polymyxin B Dosage on In-Hospital Mortality of Patients Treated with This Antibiotic. J. Antimicrob. Chemother. 66 (1), 175–179. doi:10.1093/jac/dkz390

Lakota, E. A., Landersdorfer, C. B., Nation, R. L., Li, J., Kaye, K. S., Rao, G. G., et al. (2018). Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. Antimicrob. Agents Chemother. 62 (7), e00483–00418. doi:10.1128/AAC.00483-18

Landersdorfer, C. B., Wang, J., Wirth, V., Chen, K., Kaye, K. S., Tsuji, B. T., et al. (2018). Pharmacokinetics/pharmacodynamics of Systemically Administered Polymyxin B against Klebsiella pneumoniae in Mouse Thigh and Lung Infection Models. J. Antimicrob. Chemother. 73 (2), 462–468. doi:10.1093/jac/djak409

Lee, W., Cai, Y., Lim, T. P., Teo, J., Chua, S. C., and Kwa, A. L. (2019). In Vitro pharmacodynamics and PK/PD in Animals. Adv. Exp. Med. Biol. 1145, 105–116. doi:10.1007/978-3-030-16373-0_8

Li, Y., Zheng, B., Lv, Y., Wei, M., and Shan, A. (2015). Chinese Experts Consensus on Protocol of Breakpoints Setting of New Antibacterial Agents for Clinical Trial. Chin. J. Clin. Pharmacol. 31 (11), 1069–1076.

Liu, X., Chen, Y., Yang, H., Li, J., Yu, J., Yu, Z., et al. (2021). Acute Toxicity is a Dose-Limiting Factor for Intravenous Polymyxin B: A Safety and Pharmacokinetic Study in Healthy Chinese Subjects. J. Infect. 82 (2), 207–215. doi:10.1161/jinf.2021.01.006

Liu, X., Yu, Z., Wang, Y., Wu, H., Bian, X., Li, X., et al. (2020). Therapeutic Drug Monitoring of Polymyxin B by LC-MS/MS in Plasma and Urine. Bioanalysis 12 (12), 845–855. doi:10.4155/bio-2020-0051

Nation, R. L., Goronsik, S. M., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Forrest, A., Paterson, D. L., et al. (2017). Dosing Guidance for Intravenous Colistin in Critically Ill Patients. Clin. Infect. Dis. 64 (5), 565–571. doi:10.1093/cid/ciw839

Rabanal, F., and Caji, Y. (2017). Recent Advances and Perspectives in the Design and Development of Polymyxins. Nat. Prod. Rep. 34 (7), 886–908. doi:10.1039/c7np00032e

Rigatto, M. H., Ribeiro, V. K., Konzen, D., and Zavascki, A. P. (2013). Comarison of Polymyxin B with Other Antimicrobials in the Treatment of Ventilator-Associated Pneumonia and Tracheobronchitis Caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Infection 41 (2), 321–328. doi:10.1007/s13101-012-0349-z

Ross, S., Puig, J. R., and Zaremba, E. A. (1959). Colistin: Some Preliminary Laboratory and Clinical Observations in Specific Gastroenteritis in Infants and Children. Antibi. Annu. 7, 89–100.

Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., et al. (2013). Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. Clin. Infect. Dis. 57 (4), 524–531. doi:10.1093/cid/cit354

Satin, M. J., Lewis, J. S., Weinstein, M. P., Patel, J., Humphries, R. M., Kahlmeter, G., et al. (2020). Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin. Infect. Dis. 71 (9), e523–529. doi:10.1093/cid/ciaa121

Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., et al. (2005). Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49 (9), 3624–3630. doi:10.1128/AAC.49.9.3624-3630.2005

Terayama, T., Yamakawa, K., Umemura, Y., Aihara, M., and Fujimi, S. (2017). Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Surg. Infect. 18 (3), 225–233. doi:10.1089/sur.2016.168

Tsui, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., et al. (2019). International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 39 (1), 10–39. doi:10.1002/phar.2209

Velkov, T., Thompson, P. E., Azad, M. A. K., Roberts, K. D., and Bergen, P. J. (2019). History, Chemistry and Antibacterial Spectrum. Adv. Exp. Med. Biol. 1145, 13–36. doi:10.1007/978-3-030-16373-0_3

World Health Organization (2020). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report. Available at: https://www.who.int/glass/resources/publications/early-implementation-report-2020/en/ (Accessed October 15, 2020).

Wu, X., Huang, C., Wang, H., Ji, J., Ying, C., and Xiao, Y. (2021). Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China. Drug Des. Devel Ther. 15, 2593–2603. doi:10.2147/DDDT.S313714

Xie, J., Roberts, J. A., Lipman, J., Cai, Y., Wang, H., Zhao, N., et al. (2020). Pharmacokinetic/Pharmacodynamic Adequacy of Polymyxin B against Extensively Drug-Resistant Gram-Negative Bacteria in Critically Ill, General ward and Cystic Fibrosis Patient Populations. Int. J. Antimicrob. Agents 55 (6), 105943. doi:10.1016/j.ijantimicag.2020.105943

Yahav, D., Giske, C. G., Gramatniec, A., Abadaksh, H., Tam, V. H., and Leibovici, L. (2020). New β-Lactam/β-Lactamase Inhibitor Combinations. Clin. Microbiol. Rev. 34 (1), e00115–20. doi:10.1128/CMR.00115-20

Zavascki, A. P., Goldani, L. Z., Gao, G., Superti, S. V., Lutz, L., Barth, A. L., et al. (2008). Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients. Clin. Infect. Dis. 47 (10), 1298–1304. doi:10.1086/592577

Zhao, S., Yan, L., Wang, C., and Peng, M. (2020). Clinical Analysis of Sepsis with Extensively Drug Resistant Gram-Negative Bacteria in Intensive Care Unit Treated with Polymyxin B-Based Combination Therapy. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 32 (2), 150–154. doi:10.3760/cma.j.cn121430-20200108-00028

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Bian, Liu, Hu, Feng, Chen, Bergen, Li, Li, Guo and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.